Metastatic Uveal Melanoma Clinical Trial
Official title:
Ipilimumab and Nivolumab in Combination With Immunoembolization for the Treatment of Metastatic Uveal Melanoma
Verified date | March 2024 |
Source | Thomas Jefferson University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies ipilimumab and nivolumab with immunoembolization in treating patients with uveal melanoma that has spread to the liver. Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Immunoembolization may kill tumor cells due to loss of blood supply and develop an immune response against tumor cells. Giving ipilimumab and nivolumab with immunoembolization may work better in treating patients with uveal melanoma.
Status | Active, not recruiting |
Enrollment | 14 |
Est. completion date | December 31, 2024 |
Est. primary completion date | December 31, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Histologically confirmed metastatic uveal melanoma in the liver; patients must have at least one measurable liver metastasis that is >= 10 mm in longest diameter by computed tomography (CT) scan or magnetic resonance imaging (MRI) - The total volume of the tumors must be less than 50% of the liver volume - Willingness and ability to give informed consent - Agreement to access archival tissue or agreement for tumor biopsy prior to treatment - Eastern Cooperative Oncology Group (ECOG) performance status of 0, or 1 - Serum creatinine =< 2.0 mg/dl - Granulocyte count >= 1000/mm^3 - Platelet count >= 100,000/mm^3 - Bilirubin =< 2.0 mg/ml - Albumin >= 3.0 g/dl - Prothrombin time (PT)/partial thromboplastin time (PTT) less than 1.5 times normal - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than 3 x upper limit of normal (ULN) - Alkaline phosphatase less than 1.5 times ULN (grade 1) - Women must not be pregnant or breast-feeding - Women of child-bearing potential must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 23 weeks after the last dose of nivolumab and/or ipilimumab and sexually active males must use at least two other accepted and effective methods of contraception and/or to abstain from sexual intercourse for at least 31 weeks after the last dose of nivolumab and/or ipilimumab Exclusion Criteria: - Failure to meet any of the criteria set forth in the inclusion criteria section - Previous systemic exposure to anti-CTLA-4 antibody or anti-PD1 antibody - Previous liver-directed treatments including chemoembolization, radiosphere, hepatic arterial perfusion, or drug-eluting beads; liver resection and focal ablation are permitted - Presence of symptomatic liver failure including ascites and hepatic encephalopathy - Presence of untreated brain metastases; if patients have had previous treatment for the brain metastasis, an MRI or CT scan of the brain must confirm the stabilization of the brain metastasis for more than 2 months - Presence of uncontrolled hypertension or congestive heart failure, or acute myocardial infarction within 6 months of entry - Presence of any other medical complication that implies survival of less than six months - Uncontrolled severe bleeding tendency or active gastrointestinal (GI) bleeding - Significant allergic reaction to contrast dye or granulocyte-macrophage colony-stimulating (GM-CSF) - Immunosuppressive treatments within 4 weeks prior to embolization, unless prednisone =< 5 mg or equivalent - Pregnancy or breast-feeding women - Patients with active hepatitis with serum glutamic-oxaloacetic transaminase (SGOT) and serum glutamate pyruvate transaminase (SGPT) equal or greater than 5 times normal - Biliary obstruction, biliary stent or prior biliary surgery except cholecystectomy - Positive for known human immunodeficiency virus (HIV) Infection - Uncontrolled chronic obstructive pulmonary disease or previous known pulmonary fibrosis - Active infection - Auto-immune disease including inflammatory bowel disease, lupus, rheumatoid arthritis, but not including hypothyroidism or psoriasis if condition has been stable for 2 months or greater |
Country | Name | City | State |
---|---|---|---|
United States | Sidney Kimmel Cancer Center at Thomas Jefferson University | Philadelphia | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
Sidney Kimmel Cancer Center at Thomas Jefferson University | Bristol-Myers Squibb |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Hepatic Metastasis Stabilization Rate by Response Criteria (Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) | Defined as complete response + partial response + stable disease. Rated by Response Evaluation Criteria in Solid Tumors version 1.1. The estimate of the hepatic metastasis stabilization rate will be presented with corresponding 95% confidence intervals. The method of Atkinson and Brown will be used to adjust for the two-stage design. | At the end of 4th treatment cycle (Day 84 +/- 3 days). Cycles are 21 days. | |
Secondary | Incidence of Adverse Events | Graded by National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0. Toxicity rates will be estimated with corresponding 95% confidence intervals. | Up to 1 year | |
Secondary | Progression Free Survival (PFS) | Will be estimated using the Kaplan-Meier method. | From the start of the treatment to confirmation of progression of disease, assessed up to 1 year | |
Secondary | Overall Survival | Will be estimated using the Kaplan-Meier method. | From the start of the treatment to confirmation of progression of disease, assessed up to 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03068624 -
Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
|
Phase 1 | |
Recruiting |
NCT04728633 -
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
|
Phase 2 | |
Recruiting |
NCT05987332 -
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
|
Phase 2/Phase 3 | |
Completed |
NCT01551459 -
A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma
|
Phase 2 | |
Active, not recruiting |
NCT00986661 -
A Study to Assess PV-10 Chemoablation of Cancer of the Liver
|
Phase 1 | |
Completed |
NCT01585194 -
Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma
|
Phase 2 | |
Withdrawn |
NCT01328106 -
Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma
|
Phase 2 | |
Recruiting |
NCT05075993 -
Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04552223 -
Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma
|
Phase 2 | |
Recruiting |
NCT05607095 -
Pilot Trial of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Patients With Metastatic Uveal Melanoma
|
Phase 1 | |
Active, not recruiting |
NCT01587352 -
Vorinostat in Treating Patients With Metastatic Melanoma of the Eye
|
Phase 2 | |
Active, not recruiting |
NCT03025256 -
Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease
|
Phase 1 | |
Terminated |
NCT04879017 -
FHD-286 in Subjects With Metastatic Uveal Melanoma
|
Phase 1 | |
Terminated |
NCT01814046 -
Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma
|
Phase 2 | |
Recruiting |
NCT03947385 -
Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03865212 -
Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma
|
Phase 1 | |
Active, not recruiting |
NCT05022901 -
An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma
|
Phase 3 | |
Recruiting |
NCT05282901 -
Efficacy and Safety of Pembrolizumab in Combination With Lenvatinib in Metastatic Uveal MElanoma Patients (PLUME)
|
Phase 2 | |
Recruiting |
NCT05415072 -
A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04720417 -
Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma
|
Phase 2 |